184
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Phenotypic and Genotypic Drug Susceptibility Assessment of Mycobacterium bovis Bacillus Calmette-Guérin Clinical Strains

, , , , , ORCID Icon, , ORCID Icon, ORCID Icon, & show all
Pages 459-466 | Published online: 05 Feb 2021

References

  • Global tuberculosis report. World Health Organization: 2019.
  • Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med. 1931;85–94.
  • Behr MA. BCG - Different strains, different vaccines? Lancet Infect Dis. 2002;2(2):86–92. doi:10.1016/S1473-3099(02)00182-211901655
  • Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104(13):5596–5601. doi:10.1073/pnas.070086910417372194
  • Tran V, Liu JUN, Behr MA. BCG vaccines. Microbiol Spectrum. 2014;2(1):1–11. doi:10.1128/microbiolspec.MGM2-0028-2013
  • Zhang L, Ru HW, Chen FZ, et al. Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms. Mol Ther. 2016;24(2):398–405. doi:10.1038/mt.2015.21626643797
  • Barker LF. The Immunological Basis for Immunization Series. Module 5: Tuberculosis. Geneva: World Health Organization; 2011:29.
  • Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis. 1997;24(6):1139–1146. doi:10.1086/5136429195072
  • Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23(5):476–479. doi:10.1097/01.inf.0000126593.21006.ac15131480
  • Diniz LM, Guimarães T, Oliveira M, Pinto JA, Miranda SS. Lymphadenitis caused by infection with an isoniazid- and rifampin-resistant strain of Mycobacterium bovis BCG in an infant with IFN-γ/IL-12 pathway defect. J Bras Pneumol. 2014;40(2):188–192. doi:10.1590/S1806-3713201400020001424831405
  • Gomes LHF, Otto TD, Vasconcellos ÉA, et al. Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis. J Bacteriol. 2011;193(19):5600–5601. doi:10.1128/JB.05827-1121914899
  • Sotnikova EA, Shitikov EA, Malakhova MV, et al. Complete genome sequence of Mycobacterium bovis strain BCG-1 (Russia). Genome Announc. 2016;4(2):2007–2008.
  • Schoutrop ELM, Brouwer MAE, Jenniskens JCA, et al. The stability of antimycobacterial drugs in media used for drug susceptibility testing. Diagn Microbiol Infect Dis. 2018;92(4):305–308. doi:10.1016/j.diagmicrobio.2018.06.01530025972
  • Griffith ME, Bodily HL. Stability of antimycobacterial drugs in susceptibility testing. Antimicrob Agents Chemother. 1992;36(11):2398–2402. doi:10.1128/AAC.36.11.23981489183
  • Ruesen C, Riza AL, Florescu A, et al. Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania. Sci Rep. 2018;8(1):9676. doi:10.1038/s41598-018-27962-529946139
  • Williamson DA, Roberts SA, Bower JE, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2012;16(2):216–220. doi:10.5588/ijtld.11.017822137551
  • Ho J, Jelfs P, Sintchencko V. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J Antimicrob Chemother. 2013;68(12):2915–2920. doi:10.1093/jac/dkt28423838950
  • Kanji A, Hasan R, Hasan Z. Efflux pump as alternate mechanism for drug resistance in Mycobacterium tuberculosis. Indian J Tuberc. 2019;66(1):20–25. doi:10.1016/j.ijtb.2018.07.00830797276
  • Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53(1):316–318. doi:10.1128/AAC.01302-0818955515
  • Watts MR, Taylor PC, Sintchenko V, et al. Editor’s choice: implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. Clin Infect Dis. 2011;52(1):86–88. doi:10.1093/cid/ciq00221148524
  • WHO Discussion on the Improvement of the Quality Control of BCG Vaccines. França: World Health Organization; 2005.
  • Arend SM, Van Soolingen D. Low level INH-resistant BCG: a sheep in wolf’s clothing? 2011;89–93. doi:10.1093/cid/ciq016